Alnylam Pharma (ALNY) Misses Q2 EPS by 10c

Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($0.85), $0.10 worse than the analyst estimate of ($0.75). Revenue for the quarter came in at $8.69 million versus the consensus estimate of $12.64 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

You May Also Be Interested In

• Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
• Semtech surges on strong Q2 beat and upbeat Q3 guidance
• BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform